Onkologie. 2026:20(2):98-101 | DOI: 10.36290/xon.2026.018

Leptomeningeal metastases of solid tumors

Ondřej Lukáč1, Roman Roziňák2
1 Klinika hematologie, onkologie a buněčné terapie, Univerzitní nemocnice Magdeburg, Německo
2 Klinika zobrazovacích metod, 2. LF UK a FN Motol a Homolka, Praha

Leptomeningeal metastases represent a serious complication of advanced stages of solid tumors, in which metastatic tumor cells infiltrate the meninges and cerebrospinal fluid. This is a form of metastatic involvement of the central nervous system, which is characterized by varied symptoms and is associated with a very poor prognosis. The following text summarizes the available data and current recommendations regarding the diagnosis and treatment of this serious oncological complication.

Keywords: meningeal carcinomatosis, leptomeningeal metastases, intrathecal chemotherapy.

Accepted: April 20, 2026; Published: April 28, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukáč O, Roziňák R. Leptomeningeal metastases of solid tumors. Onkologie. 2026;20(2):98-101. doi: 10.36290/xon.2026.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 28.4.2027

    References

    1. Pellerino A, Brastianos PK, Rudà R, et al. Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. Cancers (Basel). 2021;13(12):2888. Go to original source... Go to PubMed...
    2. Le Rhun E, Devos P, Weller J, et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro Oncol. 2021;23(7):1100-1112. Go to original source... Go to PubMed...
    3. Pellerino A, Brastianos PK, Rudà R, et al. Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. Cancers (Basel). 2021;13(12):2888. Go to original source... Go to PubMed...
    4. Hong J, Hao Y, Yuan J, et al. Advances in the research of leptomeningeal metastases in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2025;14(8):3216-3232. Go to original source...
    5. Morikawa A, Jordan L, Rozner R, et al. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis. Clin Breast Cancer. 2017;17(1):23-28. Go to original source... Go to PubMed...
    6. Wang YY, Ying XH, Zhang KY, et al. Leptomeningeal metastasis in triple-negative breast cancer: a retrospective study. Discov Oncol. 2025;16(1):1470. Go to original source... Go to PubMed...
    7. Groves MD. Leptomeningeal Disease. Neurosurg Clin N Am. 2011;22(1):67-78. Go to original source... Go to PubMed...
    8. Nayar G, Ejikeme T, Chongsathidkiet P, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8(42):73312-73328. Go to original source...
    9. Ahluwalia MS, Becker K, Levy BP. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. Oncologist. 2018;23(10):1199-1209. Go to original source...
    10. Nakayama T, Niikura N, Yamanaka T, et al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM). Breast Cancer. 2024;31(6):1167-1175. Go to original source...
    11. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759-772. Go to original source...
    12. Le Rhun E, Weller M, van den Bent M, et al. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2023;8(5):101624. Go to original source... Go to PubMed...
    13. Prommel P, Pilgram-Pastor S, Sitter H, et al. Neoplastic meningitis: How MRI and CSF cytology are influenced by CSF cell count and tumor type. Sci Rep. 2013;3:2109. Go to original source... Go to PubMed...
    14. Kumthekar P, Youssef M, Yang J, et al. BMRK-13 CSF tumor cell (CSF-TC) detection, quantification and biomarker assessment helps in clinical management of breast cancer and non-small cell lung cancer patients having leptomeningeal disease (FORESEE study). Neuro-Oncology Advances. 2024;6(Suppl 1):i11. Go to original source...
    15. Fuereder T, Garde-Noguera J, García-Mosquera JJ, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial Lancet Oncol. 2025;26(11):1454-1466. doi: 10.1016/S1470-2045(25)00465-6. Go to original source...
    16. Le Rhun E, Wallet J, Mailliez A, et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol. 2020;22(4):524-538. Go to original source... Go to PubMed...
    17. Oberkampf F, Gutierrez M, Trabelsi Grati O, et al. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro Oncol. 2023;25(2):365-374. Go to original source... Go to PubMed...
    18. Fan C, Jiang Z, Teng C, et al. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial. ESMO Open. 2024;9(4):102384. Go to original source... Go to PubMed...
    19. Glitza Oliva IC, Ferguson SD, Bassett R Jr, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023;29(4): 898-905. Go to original source...
    20. Le Rhun E, Gramatzki D, Kraehenbuehl L, et al. IT-IO: Intrathecal administration of nivolumab and ipilimumab in combination with systemic combination of nivolumab and ipilimumab in patients with non-small cell lung cancer or melanoma and newly diagnosed leptomeningeal metastasis, a multicentric phase I study. J Clin Oncol. 2025;43(Suppl 16):2029. Go to original source...
    21. Fan C, Hu Y, Teng C, et al. Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study). Neuro Oncol. 2025;27(6):1559-1566. Go to original source...
    22. Yang JCH, KIM SW, Kim DW, et al. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020;38(6):538-547. Go to original source... Go to PubMed...
    23. Bauer TM, Shaw AT, Johnson ML, et al. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol. 2020;15(1):55-65. Go to original source... Go to PubMed...
    24. Hulsbergen AFC, Claes A, Kavouridis VK, et al. Discordance in receptor status between primary breast cancer and brain metastases. Crit Rev Oncol Hematol. 2020;145:102820.
    25. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-1437. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.